NCT03655691View on ClinicalTrials.gov

ET-01 in Subjects With Lateral Canthal Lines, LCL-207

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

November 9, 2018

Study Completion Date

April 11, 2019

Conditions
Lateral Canthal LinesCrow's Feet
Interventions
BIOLOGICAL

Vehicle

Vehicle Formulation

BIOLOGICAL

botulinum toxin, Type A

botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline

BIOLOGICAL

botulinum toxin, Type A

botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline

Trial Locations (6)

23502

Virginia Clinical Research, Inc., Norfolk

33137

Baumann Cosmetic & Research Institute, Miami

33401

Research Institute of the Southeast, LLC, West Palm Beach

33781

Radiant Research, Inc., Pinellas Park

70006

Dermatology NOLA Inc., Metairie

78746

Westlake Dermatology Clinical Research Center, Austin

Sponsors
All Listed Sponsors
lead

Eirion Therapeutics Inc.

INDUSTRY